Design: 13,299 randomized patients, double-blind, active-comparator trial (modified intention-to-treat: 6,586 tirzepatide
10.1016/j.tins.2009.01.001 55 HousleyG
Seek medical advice if fatigue: Persists beyond several months without improvement, despite adequate nutrition and hydration Worsens progressively or becomes debilitating, significantly impairing daily activities or work capacity Is accompanied by severe or persistent gastrointestinal symptoms (intractable nausea, vomiting, diarrhoea, abdominal pain) Occurs alongside signs of dehydration (dark urine, dizziness, reduced urine output, dry mouth) Is associated with symptoms of hypoglycaemia (tremor, sweating, confusion, palpitations), particularly in patients taking concurrent insulin or sulphonylureas Urgent medical attention is required if patients experience: Severe abdominal pain , especially if radiating to the back, which may indicate pancreatitisa rare but serious adverse effect of GLP-1 medications
= 0.034)
Designed in an easy-to-use tablet format, this product provides a convenient alternative to injectable GLP-1 options
